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Abstract 
Objective: The American Heart Association has endorsed depression as a cardiac risk factor 
and recommends screening as part of routine practice. This has been met with controversy due 
to inconsistencies in the data linking depression treatment to better cardiovascular outcomes. 
Our objective was to prospectively assess the association between depression treatment 
(defined as being prescribed antidepressant medication) and major adverse cardiovascular 
events (MACE) in patients referred for exercise stress tests. 
Methods: 2385 consecutive patients presenting for myocardial perfusion exercise stress tests 
underwent a sociodemographic, medical, and psychiatric interview (PRIME-MD) and completed 
the Beck Depression Inventory (BDI). History of CVD and antidepressant use was self-reported 
and verified via chart review. Participants followed over an 8.8 year follow-up, and information 
regarding MACE incidence (including cardiac mortality, non-fatal myocardial infarction, 
revascularization procedures, cerebrovascular events) was obtained from provincial 
administrative databases.  
Results: 8% (n=190) of the sample were taking antidepressants at baseline, 41% (n=916) had 
a history of CVD, and 38.7% (n=921) had depression according to the PRIME-MD or BDI. 
Antidepressant treatment was associated with a 30% reduced risk of MACE (HR=0.697; 
95%CI=0.504-0.964; p=.029). A 46% reduction in risk was associated with antidepressant 
treatment among those without CVD (HR=0.542; 95%CI=0.299-0.981; p=.043). In depressed 
patients, a 33% reduction in risk of MACE associated with antidepressant use was seen 
(adjusted HR=0.674; 95%CI=0.440-1.033; p=.07). 
Conclusions: Antidepressants may be cardio-protective among patients presenting for stress 
testing independent of risk factors including CVD and depression. Results support treating 
depression with antidepressants in this population to reduce risk of MACE. 
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Introduction 
Multiple studies have documented a disproportionately high rate of depressive symptomatology 
and clinical depression (i.e., major depressive disorder, MDD) among individuals with or at 
elevated risk for cardiovascular disease (CVD) (Barefoot et al., 2000; Carney et al., 1987; 
Frasure-Smith, Lesperance, & Talajic, 1993; Frasure-Smith, Lesperance, & Talajic, 1995b; 
Lane, Carroll, Ring, Beevers, & Lip, 2002; Steeds, Bickerton, Smith, & Muthusamy, 2004). 
Several reports have also linked depression to worse cardiovascular outcomes in both healthy 
and established populations, including an increased risk of major cardiovascular events, all-
cause mortality, and poorer quality of life (Anda et al., 1993; Ariyo et al., 2000; Barefoot et al., 
1996; Blumenthal et al., 2003; Burg, Benedetto, & Soufer, 2003; Frasure-Smith & Lesperance, 
2005) 
The amount and robustness of this data has recently lead the American Heart Association 
(AHA) to endorse depression as a cardiac risk factor, and now recommends depression 
screening as part of routine practice (Lichtman et al., 2014). Despite the compelling nature of 
this recommendation, it has been met with controversy due to a paucity of data linking 
depression treatment, including psychological and pharmacological-based treatments (Joynt & 
O'Connor, 2005) to better cardiovascular outcomes (Thombs et al., 2008; Thombs et al., 2013). 
Indeed, while there is evidence that depression screening can identify those at risk for worse 
cardiovascular outcomes (Elderon, Smolderen, Na, & Whooley, 2011), few studies have actually 
linked depression treatment to improved cardiovascular outcomes (Taylor et al., 2005). Further, 
among those that have, (Davidson et al., 2013; Katon et al., 2010) they did not assessed the 
role of antidepressants.  
In this study, we prospectively assessed the association between depression treatment (defined 
as being prescribed antidepressant medication at baseline) and the occurrence of major 
adverse cardiovascular events (MACE) over an average of 8.8 years in patients undergoing 
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myocardial perfusion exercise stress tests, both in the entire sample and in those with and 
without evidence of CVD at baseline. As a secondary analysis, we also assessed the impact of 
antidepressant treatment in the subgroup of patients who had depression at baseline. 
 
Methods 
Participants 
This is a sub-analysis of the Depression Effects on Coronary Artery Disease Events (DECADE) 
prospective observational Study, so the methods have been described elsewhere (Paine, 
Bacon, et al., 2016; Pelletier et al., 2015). Briefly, the sample included 2460 consecutive 
patients who presented to the Montreal Heart Institute (MHI) for diagnostic myocardial perfusion 
single photon emission computed tomography (SPECT) exercise stress testing between 
September 1998 and June 2002. All patients who were presenting for nuclear exercise stress 
tests who met inclusion criteria, were approached to participate, meaning our sample was not a 
randomly selected or a convenience sample. However, some patients were occasionally 
“missed” due to staffing limitations, likely at a rate estimated to be less than 5%, but this would 
have occurred at random. Patients were eligible if they were between the ages of 18 and 75, 
medically stable, and were fluent in English or French. Patients were excluded if they had a 
documented medical condition that conferred greater risk of illness morbidity than CVD (e.g., 
cancer); if they were inpatients at the time of their stress test; or if they were medically unstable 
(e.g., major cardiac event in the last 4 weeks). This protocol was approved by the MHI’s ethics 
review board (ID: 07-965) and participants provided written, informed consent.  
Study Procedure 
Patients were approached after completing their exercise stress test. Patients underwent a 
medical history interview that included providing information about medications, followed by a 
structured psychiatric interview (PRIME-MD) (Spitzer et al., 1994), and completed the Beck 
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Depression Inventory (BDI). All medical diagnoses, procedures and events occurring during the 
period between recruitment and December 31st 2008 were obtained from Quebec’s healthcare 
administrative databases (RAMQ and Medecho) which record all billable acts, visits and 
interventions in the province of Quebec. Official mortality data over the same period was 
obtained from the Institut de la statistique du Québec (ISQ), which records date of death and 
primary and secondary causes.  
Baseline assessments  
All participants underwent SPECT myocardial perfusion exercise stress testing (treadmill, Bruce 
protocol) according to standard procedures (Anagnostopoulos et al., 2004). Ischemia diagnoses 
were made by experienced Nuclear Medicine Physicians. Data regarding socio-demographics, 
health behaviors, clinical risk factors, history of CVD and medications were self-reported and 
verified via interview. History of CVD was defined as having had a previous MI, percutaneous 
coronary intervention (PCI), coronary artery bypass graft (CABG), or stroke. 
Depression measures:  
Depression was determined by assessing the presence of a depressive disorder (i.e., clinical 
depression) or the presence of clinically significant depressive symptoms. Depressive disorders 
(including major and minor depression, dysthymia, and bipolar disorder) were assessed at 
baseline using the Primary Care Evaluation of Mental Disorders (PRIME-MD)(Spitzer et al., 
1994). This instrument was also used to assess the anxiety disorders (panic disorder, 
generalized anxiety disorder, ‘other’ anxiety disorder) for descriptive and adjustment purposes. 
The PRIME-MD is a brief, semi-structured psychiatric interview that was developed to identify 
the most common DSM-IV disorders seen in primary and tertiary care settings. Validation 
studies have reported a specificity of 88%, a sensitivity of 83%, and a kappa of .71 for the mood 
disorder module, which is comparable to longer interviews such as the Structured Clinical 
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Interview for DSM-IV (Spitzer, Kroenke, & Williams, 1999; Spitzer et al., 1994). An electronic 
version of the interview was administered by an experienced PhD-level psychology student 
and/or licensed clinical psychologist. 
Depressive symptomatology was measured using the Beck Depression Inventory (BDI) (Beck & 
Steer, 1987; Beck, Steer, & Garbin, 1988), which is a 21-item self-report questionnaire that is 
one of the most commonly used instruments in studies assessing depression in CAD patients. It 
has excellent internal consistency (α = .90-.91) and high construct validity (r = .89) (Beck et al., 
1988). BDI scores ≥ 10 are considered clinically significant (denoting mild depression (Moullec, 
Plourde, Lavoie, & Bacon, 2015)) and have been shown to be predictive of worse 
cardiovascular outcomes (Lesperance, Frasure-Smith, Talajic, & Bourassa, 2002). A patient 
was classified as having depression if they met criteria for one or more mood disorders 
according to the PRIME-MD (which uses a diagnostic algorithm based on DSM-IV criteria) or 
had a score on the BDI ≥ 10, which has been shown to be clinically significant (Frasure-Smith, 
Lesperance, Juneau, Talajic, & Bourassa, 1999; Frasure-Smith, Lesperance, & Talajic, 1995a).  
Follow-up outcome assessment 
MACE was categorized according to the standard protocol published by the WHO (Luepker, 
Evans, McKeigue, & Reddy, 2004) and included: cardiac mortality, non-fatal MI, 
revascularization procedures, and cerebrovascular events. Cause of death was coded 
according to the ICD system. The primary reported cause of death was used to define cause of 
mortality. All International Classification of Disease (ICD)-9 (before April 1st 2006), ICD-10 
(beginning April 1st 2006), Manuel des médecins omnipraticiens et spécialistes (for intervention 
procedures), and ISQ cause of death coding classifications used in the study have been 
previously reported (Pelletier et al., 2015).  
Data reduction and statistical analyses 
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All data were analyzed using SAS Version 9.3 (SAS Institute, Cary, North Carolina, USA). Of 
the 2460 participants recruited, 75 were lost to follow-up due to missing data in the matching 
process (such as the absence of birth date) with the RAMQ databases, resulting in a final 
sample of 2385 patients. Rubin's rules (Rubin, 1987) were followed for our missing data 
analysis procedures, using multiple imputation (Barzi & Woodward, 2004) with missing at 
random (MAR) assumptions. Using the PROC MI method of multiple multivariate imputation in 
SAS, we independently analyzed 20 copies of the data. PROC MIANALYZE was used 
according to Harrell’s guidelines (Harrell, 2001). One-way general linear models and 
χ2 analyses were used to compare baseline sociodemographic and clinical characteristics.  
Cox regression models were used to assess the main effect of antidepressant use on time to 
first MACE. The first occurrence of the outcome variable was taken as the event for analysis. 
Owing to the known association of the following variables with CVD outcomes (Rosengren et 
al., 2004), regression models were adjusted for the following a-priori defined covariates: 
baseline age, sex, smoking status, BMI, history of CVD (except for CVD stratified analyses), 
diabetes, hypertension, dyslipidemia, SPECT evidence of exercise-induced myocardial 
ischemia (on index stress test), baseline anxiety disorder (PRIME-MD), and baseline depression 
(except for depressed subgroup analyses).  
 
Results 
Sample characteristics 
Sample characteristics are presented in Table 1. Briefly, the sample was 67% male, nearly 99% 
white, with a mean age of 56.8 [±8.5] years. A total of 41% had a history of CVD, 41% had 
ischemia on the index stress test, and 30% experienced a MACE during the follow-up (mean 
time to MACE=6.8 [±3.09] years). Out of the total sample of 2385 patients, only 8% (N=190) 
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were taking antidepressants at baseline, the majority of which (70%) were selective serotonin 
reuptake inhibitors (SSRI’s). A total of 38.7% (n=921) of the sample had depression 
characterised by the presence of a depressive disorder (PRIME-MD) or a BDI score ≥10.  In the 
patients who were identified as depressed (N=921), only 12.6% (N=116) were taking 
antidepressants. Only 14% (N=329) of our sample had major depression (per 
diagnosis/classification using the PRIME-MD), however out of those who were taking 
antidepressants (N=190) nearly 30% of those individuals had major depression. In the patients 
who were identified as having an anxiety disorder (n=475), 75 patients were taking an 
antidepressant, but only 11 patients with anxiety disorders only (i.e., no cormorbid depression) 
were taking antidepressants. 
 
Sample characteristics presented as a function of antidepressant treatment at baseline are also 
presented in Table 1. Group differences were evident for certain characteristics: patients taking 
antidepressants were younger and less likely to be male. Conversely, in patients not taking 
antidepressants, there were significantly higher rates of cohabitating, current smokers, 
hyperlipidemia, beta-blocker use, aspirin use, and significantly higher resting systolic and 
diastolic blood pressure (p’s <.05). Across the whole sample, rates of depressive and anxiety 
disorders were also higher in patients not taking antidepressants, but BDI score was higher in 
patients taking antidepressants (p’s <.001).  
 
Association between antidepressant use and risk of MACE in the whole sample 
Unadjusted analyses examining the association between antidepressant use and MACE 
revealed a significant reduction in risk of 35% of MACE (HR=0.651; 95%CI = 0.474-0.896; p = 
.008). After adjustment for covariates including baseline depression, the use of antidepressants 
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was still associated with a significant 30% reduced risk of MACE over the follow-up (adjusted 
HR=0.697; 95%CI =0.504–0.964; p=.029) (see Table 2, figure 1).  
 
Association between antidepressant use and risk of MACE in patients with vs. without 
CVD 
There were also differences in MACE risk associated with antidepressant use as a function of 
CVD status in stratified analyses (see Table 3). In unadjusted analyses, patients without CVD 
had a 39.5% reduced risk of MACE that was marginally significant (HR = 0.605; 95%CI = 0.364 
– 1.008; p = .054). Though risk estimates were in the same direction, there was no significant 
reduction in risk of MACE observed among those with CVD (HR = 0.715; 95%CI= 0.461 – 
1.110; p=.135). After adjustment for covariates, the reduced risk of MACE associated with 
antidepressant use among patients without CVD was significant and increased to 46% (adjusted 
HR = 0.542; 95%CI = 0.299 – 0.981; p = .043); however, the risk of MACE associated with 
antidepressant use among those with CVD did not reach significance after covariate adjustment 
(adjusted HR = 0.690; 95%CI = 0.437 - 1.091; p = .113) (see figure 2). 
 
Association between antidepressant use and risk of MACE in depressed patients 
Among patients identified as depressed at baseline, only 12.6% (n=116) were taking 
antidepressants. In secondary subgroup analyses among depressed patients, results revealed a 
significant 37% reduction in risk of MACE associated with antidepressant use (HR = 0.629; 
95%CI = 0.414-0.957; p=0.030). Though risk estimates were in the same direction, this became 
a non-significant trend after covariate adjustment (adjusted HR=0.674; 95%CI =0.440-1.033; 
p=.07) (see Table 4).  
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Sensitivity analyses 
Supplementary analyses adjusting for depression using different definitions (i.e., major 
depression/minor depression and continuous BDI scores) revealed a similar pattern of results 
(data not shown). Additionally, supplementary analyses excluding anxiety disorders as a 
covariate (due to potential multicollinearity with depression) also revealed a similar pattern of 
results (data not shown). Finally, we conducted a sensitivity analysis including the four non a-
priori defined covariates that were found to be significantly different between those taking and 
not taking anti-depressants at baseline (i.e., cohabitation and use of beta-blockers, lipid 
lowering medication, and aspirin), both in the whole sample and in those identified as depressed 
at baseline.  These analyses also revealed a similar pattern of results, which can be found in 
supplementary content (Tables S1 and S2).  
 
Discussion 
We prospectively assessed the association between antidepressant depression treatment 
(defined as being prescribed antidepressant medication, primarily SSRI’s) and occurrence of 
MACE in patients with and without CVD undergoing SPECT exercise stress tests, over an 
average 8.8 year follow up period. We observed a 30% reduction in 8-year risk of MACE among 
patients prescribed antidepressants after adjusting for several important covariates including 
age, sex, traditional risk factors, CVD history, and the presence of baseline anxiety and 
depressive disorders. This indicates that among patients with or at risk for CVD, 
antidepressants may be cardio-protective, irrespective of baseline depression status. 
Additionally, in stratified analyses, we observed a 46% reduction in risk associated with 
antidepressant use among those without CVD at baseline that was not observed among 
patients with a history of CVD. This suggests that the cardio-protective effects of antidepressant 
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treatment may be even stronger among patients early in the disease process, before the 
occurrence of any major cardiac events. Finally, we found a 37% reduced risk of MACE 
associated with antidepressant use in the subgroup of patients identified as depressed 
according to the PRIME-MD or BDI at baseline, which became a trend after full covariate 
adjustment. Given that risk estimates among depressed patients were consistent with those for 
entire sample suggests that this may have been due to reduced power given a lower sample 
size in subgroup analyses. Indeed, only 12.6% (n=116) of patients identified as depressed at 
baseline were taking antidepressants. This is noteworthy considering our definition of definition 
includes those who met diagnostic criteria for a depressive disorder according to the PRIME-MD 
and/or had a score of 10 or greater on the BDI. The reasons for such low rates of depression 
treatment are not known, but they are likely due to the fact that depression was not routinely 
assessed at our tertiary care cardiology hospital, so we were likely detecting either new or 
previously undiagnosed cases of depression. Nonetheless, despite the apparently low rates of 
antidepressant prescription among patients who were depressed, our overall pattern of results 
suggests that antidepressant treatment may be cardio-protective in this population, and 
particularly among those without established CVD. They also suggest that antidepressant use, 
and SSRI’s in particular (which were the most commonly prescribed in our population) may also 
reduce the risk for subsequent cardiovascular events among depressed patients, which 
addresses a major gap in the literature.  
Taken together, our findings are consistent with those of three other studies that observed 
significantly reduced risks of MI associated with SSRI-related antidepressant use (Kimmel et al., 
2011; Noordam et al., 2016; Sauer, Berlin, & Kimmel, 2001). Our findings are also in line with 
trial results reported by Taylor et al., who found that antidepressant use was associated with a 
43% reduction in risk of all-cause mortality and non-fatal MI among depressed post-MI patients 
in a secondary analysis of the ENRICHD Trial data (Taylor et al., 2005). Glassman et al. (2009) 
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showed a reduced risk of cardiac events in patients treated with sertraline, however this study 
did not show a decreased rate of cardiac mortality between sertraline and placebo (Glassman, 
Bigger, & Gaffney, 2009). Our results are inconsistent with the trial results of Zuidersma et al. 
(Zuidersma, Conradi, van Melle, Ormel, & De Jonge, 2012), neither of whom found a significant 
association between antidepressant therapy and future risk for cardiovascular events or 
mortality. There are several possible explanations for these disparate results: in Zuidersma et 
al.’s study, patients in the “treatment” group received both pharmacological and 
psychotherapies, which may act on cardiovascular outcomes in different ways. Further, the trial 
employed a “usual care” control group, 16% of which were receiving some form of treatment for 
depression and may have diluted group differences. Of note, they conducted a sensitivity 
analyses of all those receiving some form of depression treatment (in either group) and found a 
significant reduction in all-cause mortality (HR=0.52, 95% CI 0.28-0.97), which provides support 
for this hypothesis. Of note, their HR’s were in the right direction (e.g., Zuidersma et al.’s 
mortality HR=0.74, 95% CI: 0.41 -1.33).  Although our findings are observational, they do add to 
a body of literature supporting a potential protective effect of antidepressant use among patients 
with or at risk for CVD. 
We were surprised to find that in our cohort, depression itself was not predictive of MACE when 
we adjusted for depression status in our analyses which demonstrated antidepressant use to be 
protective of MACE risk. The fact that the effect of antidepressants on risk of MACE was 
independent of depression status may seem counter-intuitive; however, it is likely that many of 
the patients taking antidepressants at baseline who were not depressed were in partial 
remission at the time of the baseline evaluation. This may have masked depression effects, 
because our baseline evaluation would have likely categorized remitted or partially remitted 
patients as non-depressed by failing to meet diagnostic or cut-off criteria. Since we did not 
collect data on psychiatric status prior to the entry into the study, we are unable to confirm this 
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hypothesis. However, the fact we observed a comparable reduction in risk of MACE in our 
subgroup of depressed patients suggests that antidepressants are indeed cardio-protective 
among depressed patients.  
 
Mechanisms 
Several studies have shown that antidepressants, particularly SSRI’s, are associated with 
reduced platelet and blood serotonin levels (Schlienger & Meier, 2003; Wozniak, Toska, Saridi, 
& Mouzas, 2011), suggesting an inhibitory effect on platelet activation which may be protective 
for CVD. Given the vast majority (70%) of patients in our study were taking SSRI’s provides 
support for this hypothesis. Further, depression is associated with an over-expression of C-
reactive protein and pro-inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-1 and IL-6) that stimulate 
central serotonin (5-HT) neurotransmission (Dinan, 2008), which has been linked to both MI and 
CVD (Wozniak et al., 2011). Thus, treatment of depression using antidepressants (and SSRI’s 
in particular) may not only reverse or dampen the pro-inflammatory effects of depression but 
may also act directly on platelets, as mentioned above, to reduce CVD risk. In addition to direct 
pharmacological pathways, depression treatment may also improve many of the poor health 
behaviors that often accompany depression (e.g., increased smoking, poor dietary habits, 
greater physical inactivity, poor treatment adherence) (Lavoie & Fleet, 2000). While those on 
antidepressants at baseline had higher rates of current smoking and comparable BMI’s as those 
not on antidepressants, the lack of follow-up data on these variables makes it impossible to 
know if treatment was successful at improving these risk factors. However, the size of our 
observed effects is comparable with other “behavioral” predictors of improved cardiovascular 
risk such as physical activity (Tambalis et al., 2016), dietary habits and alcohol intake, (Yusuf et 
al., 2004) all of which may be influenced by changes (improvements) in mood, which provides 
partial support for this hypothesis. 
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Finally, while unlikely, it is possible that patients who were taking antidepressants may have 
visited physicians more often, and as a result have received better overall health monitoring and 
treatment, independent of any specific effect of antidepressants. However, the fact we observed 
a cardio-protective effect associated with antidepressant use independent of depression status 
suggests that mechanisms are more likely to be pharmacological than behavioral.  
 
Limitations and strengths 
This study should be interpreted with caution in light of some limitations: First, this was not a 
randomized study of the effects of antidepressants on MACE, which would not have been 
ethical in a prospective observational study, so results should be interpreted with this in mind. 
Second, though we have data on what antidepressants patients were taking (primarily SSRI’s), 
we do not have data on dose, length of treatment, or adherence (Sansone & Sansone, 2012). 
Thus, any potential beneficial physiological effects associated with antidepressant use (e.g., 
anti-platelet or anti-inflammatory) would only be expected to occur as long as patients were 
taking the medication. Similarly, we have no information on psychiatric history, or whether 
patients were receiving other forms of depression treatment (e.g., psychotherapy) at baseline or 
over the follow-up. However, this level of data collection is typical of large-scale epidemiological 
cohort studies in this area. Second, the lack of follow-up data on changes in health behaviors 
(that may have been mediators of our observed depression treatment effects) is a limitation. 
However, this is consistent with similarly designed studies with prolonged follow-up periods from 
baseline (e.g., (Glassman et al., 2009; Paine, Hinderliter, et al., 2016; Perez-Cornago et al., 
2016; Tambalis et al., 2016)). We were also unable to obtain a more detailed measure of 
ischemia quantification to include information such as Duke Score or the magnitude/location of 
ischemia, which could be considered a limitation. Given the prospective nature of this study and 
lengthy follow-up, there may be concerns that antidepressant treatments have changed. 
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However, SSRI’s were prescribed for the vast majority of patients in this study (70%) and 
remain the most common class of pharmacotherapy for depression to this day, so we are 
confident our results remain highly relevant (Nassan et al., 2016). Finally, this was a primarily 
male (67%) and white (99%) sample, and may therefore not be representative of the general 
population. However, the proportions of men and women in this study are consistent with 
referral statistics to nuclear exercise stress tests (Carney et al., 2003; Yusuf et al., 2004). 
Despite the above limitations, this study has several notable strengths. To our knowledge, this is 
first study to date to examine the impact of antidepressant treatment on the prospective risk of 
MACE among patients with and at risk for CVD. The use of valid, reliable measures to assess 
depression (PRIME-MD and BDI) is another important strength. The large sample size 
(n=2460), consecutive recruitment, and the inclusion of both men and women increases the 
generalizability of the findings. We also linked antidepressant use to reduced risk for MACE 
after adjustment for several important covariates, including CVD history and the presence of 
anxiety and depressive disorders, which attest to the robustness of the findings. We used 
multiple imputation procedures to deal with missing data that increased the reliability and 
representativeness of our analyses. Finally, the relatively long follow-up period (8.8 years) and 
the use of objective administrative database data to measure cardiovascular outcomes are 
other important strengths. 
 
Conclusion 
Our findings indicate a potential cardio-protective effect of antidepressants on risk for MACE 
over an 8.8-year follow-up among patients presenting for exercise stress tests independent of 
traditional risk factors including baseline depression and CVD history. However, the cardio-
protective effect of antidepressants was strongest among those without a history of CVD. 
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Finally, we found significantly reduced risk of MACE associated with antidepressant use in the 
subgroup of patients identified as depressed at baseline, which became a trend after full 
covariate adjustment. Though only a trend, risk reduction estimates for MACE in depressed 
patients (33%) were comparable to those observed in the whole sample (30%), suggesting 
antidepressant treatment may indeed reduce the risk for subsequent cardiovascular events 
among depressed patients, which addresses a major gap in the literature. Future studies, 
particularly RCT’s, are encouraged to further examine the efficacy of depression treatment 
(pharmacological and psychotherapeutic) on cardiovascular outcomes, to further elucidate 
mechanisms of action. 
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Table 1: Sample characteristics 
  
All 
No 
Antidepressant 
Use (n=2195) 
Antidepressant 
Use 
(n=190) 
 
F/χ2 
 
P 
N 
missing 
 
Demographics 
Age (years) 56.8(8.52) 56.9(8.56) 55.7(7.96) 3.71 .05 0† 
Sex (% Male) 67.4(1610) 69.0(1511) 51.0(97) 25.1 <.001 2† 
BMI (kg/m2) 27.5(4.79) 27.6(4.75) 26.7(5.21) 2.11 .15 1570† 
Race (% White) 98.7(2184) 98.6(2008) 100(175) 2.52 .11 177 
Cohabiting (%) 71.0(953) 72.3(896) 54.9(56) 13.9 <.001 1048 
Education 
(greater than 12 
years; %) 
58.2(781) 58.2(721) 58.8(60) 0.015 .90 1048 
 
Psychiatric Status 
Any* Depression 
(%) 
38.7(921) 36.7 (805) 61.0 (116) 43.57 <.001 9 
PRIME-MD 
Depressive 
Disorder (%) 
24.0(572) 22.4(491) 42.6(81) 39.2 <.001 8† 
PRIME-MD Major 
Depression (%) 
13.8(329) 12.5(273) 29.5(56) 43.28 <.001 8† 
PRIME-MD Minor 
Depression (%) 
9.19(219) 9.22(202) 8.95(17) 0.02 .90 8† 
PRIME-MD 
Bipolar Disorder 
(%) 
0.92(22) 0.59(13) 4.74(9) 33.26 < .001 7† 
PRIME-MD 
Dysthymia (%) 
6.29(150) 5.29(116) 17.9(34) 48.01 < .001 7† 
PRIME-MD 
Anxiety Disorder 
(%) 
20.0(476) 18.3(401) 39.5(75) 49.0 <.001 10† 
BDI Score ≥ 10 
(%) 
29.5(707) 27.5(604) 54.2(103) 59.6 <.001 122 
Mean BDI Score 8.05(7.25) 7.54(6.68) 13.7(10.4) 129.8 <.001 122† 
 
Clinical Characteristics 
Current Smoker 
(%) 
23.4(483) 22.7(431) 30.7(51) 7.40 .025 326† 
Alcohol Heavy 
Consumption** 
(%) 
6.0(81) 5.9(74) 6.8(7) 0.20 .90 1042† 
CVD history (%) 41.4(916) 41.8(851) 36.6(64) 1.81 .18 178† 
       
Diabetes (%) 10.8(238) 11.0(223) 8.6(15) 0.96 .33 179† 
Hypertension (%) 43.5(961) 43.9(894) 38.3(67) 2.09 .15 179† 
Hyperlipidemia 
(%) 
59.2(1309) 60.0(1221) 50.3(88) 6.26 .01 178† 
 
Stress Test Results 
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Ischemia (%) 40.8(952) 41.1(881) 37.6(70) 0.85 .36 58† 
Baseline HR 
(bpm) 
66.4(12.1) 66.3(12.2) 68.0(11.1) 3.28 .07 56 
Baseline SBP 
(mmHg) 
135.7(20.3) 136.2(20.2) 130.6(21.1) 12.8 <.001 60 
Baseline DBP 
(mmHg) 
85.8(11.4) 86.0(11.4) 83.2(11.5) 11.0 <.001 60 
 
Medications 
Ace Inhibitor (%) 16.9(372) 16.5(336) 20.6(36) 1.87 .17 182 
Beta Block (%) 35.8(791) 36.5(742) 28.0(49) 5.10 .024 183 
Diuretic (%) 7.52(166) 7.3(148) 10.3(18) 2.09 .15 182 
Ca-Channel 
Blockers (%) 
18.5(408) 18.5(377) 17.7(31) 0.07 .79 181 
Lipid-Lowering 
Medication (%) 
49.3(1088) 49.8(1013) 42.3(74) 3.67 .06 181 
Anti-hypertension 
Medication Use 
(%) 
55.3(1221) 55.7(1131) 51.4(90) 1.17 .28 182 
Anti-ischemic 
Medication Use 
(%) 
55.3(1219) 55.8(1132) 49.7(87) 2.41 .12 185 
Aspirin (%) 55.9(1167) 53.7(1090) 44.0(77) 6.11 .013 185 
Antidepressant 
Use (%) 
8.0(190) - - - - 3† 
 
Cardiovascular Outcomes 
Mean time to 
MACE 
(days) 
6.84(3.09) 6.80(3.11) 7.20(2.87) 2.93 .09 1† 
Incidence of 
MACE (%) 
30.2(721) 28.5(680) 21.0(40) 8.13 .004 1† 
Presented as Mean (SD) or % (n). *defined as any depressive disorder on the PRIME-MD or 
BDI ≥10); **alcohol consumption defined as greater than 3 drinks per day. † Variables included 
in the imputation procedure  
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Table 2. Unadjusted (top), adjusted for depression only (middle) and fully adjusted 
(bottom) association between antidepressant use and risk of MACE 
 β-estimate Hazard Ratio 95% Confidence  
Limits 
p-value 
Unadjusted 
Antidepressant use -0.429 0.651 0.474-0.896 .008 
     
Adjusted for depression only 
Antidepressant use -0.435 0.648 0.470-0.892 .008 
Depression* 0.025 1.025 0.880-1.194 .750 
     
Fully adjusted 
Antidepressant use -0.361 0.697 0.504–0.964 .029 
Depression* 0.033 1.033 0.875–1.221 .699 
Anxiety Disorder 0.174 1.189 0.971–1.456 .093 
Sex 0.218 1.244 1.018–1.520 .033 
CVD history 0.359 1.432 1.204–1.704 <.0001 
Age 0.021 1.021 1.011–1.030 <.0001 
Exercise-induced 
(SPECT) myocardial 
Ischemia  
0.602 1.826 1.548–2.153 <.0001 
Current smoking status 0.280 1.323 1.084–1.613 .006 
Diabetes 0.218 1.244 0.995–1.554 .055 
Hypertension 0.173 1.189 1.017–1.391 .030 
Dyslipidemia 0.101 1.107 0.927–1.320 .261 
BMI -0.011 0.989 0.955–1.025 .532 
Note: All variables coded as absent (0) or present (1), with the exception of BMI. * indicates 
depression diagnosis per PRIME-MD or BDI ≥ 10 
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Table 3. Association between antidepressant use and risk of MACE, stratified by CVD 
status (includes index stress test result). 
Differences by CVD history β-estimate Hazard Ratio 95% Confidence Limits p-value 
No CVD history 
Unadjusted analysis     
Antidepressant use -0.502 0.605 0.364 – 1.008 .054 
Depression * 0.038 1.039 0.824 – 1.310 .749 
     
Adjusted analysis     
Antidepressant use -0.613 0.542 0.299 – 0.981 .043 
Depression * 0.119 1.127 0.859 – 1.479 .390 
     
CVD history     
Unadjusted analysis     
Antidepressant use -0.336 0.715 0.461 – 1.110 .135 
Depression * 0.026 1.027 0.832 – 1.268 .806 
     
Adjusted analysis     
Antidepressant use -0.371 0.690 0.437 – 1.091 .113 
Depression * -0.010 0.990 0.781 – 1.256 .936 
*either depression diagnosis per PRIME-MD, or BDI score > 10. Adjusted analyses adjusted for 
anxiety disorder, age, exercise-induced SPECT Ischemia, current smoking status, presence of 
diabetes, hypertension, dyslipidemia, BMI, and sex, plus depression (shown). 
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Table 4.  
Adjusted association between treatment of antidepressant use in depressed patients and 
risk of MACE (n=921) 
 β-estimate Hazard Ratio 95% Confidence Limits p-value 
Unadjusted analysis 
Antidepressant use -0.463 0.629 0.414-0.957 .030 
     
Adjusted analysis 
Antidepressant use -0.394 0.674 0.440–1.033 .070 
Anxiety Disorder 0.093 1.098 0.855–1.410 .465 
Sex (male) 0.193 1.213 0.902–1.631 .201 
CVD history 0.349 1.418 1.062–1.894 .018 
Age 0.017 1.017 1.003–1.032 .021 
Exercise-induced 
(SPECT) myocardial 
Ischemia  
0.679 1.973 1.516–2.566 <.0001 
Current smoking status 0.331 1.393 0.999–1.941 .050 
Diabetes 0.347 1.415 1.008–1.987 .045 
Hypertension 0.075 1.078 0.836–1.389 .564 
Dyslipidemia 0.032 1.033 0.779–1.370 .823 
BMI -0.016 0.985 0.940–1.031 .498 
Note: All variables coded as absent (0) or present (1), with the exception of BMI. Depression 
characterized as PRIME-MD or BDI ≥10. Depression with no treatment used as reference point 
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Figure 1. Kaplan Meier survival curve for the use of anti-depressants on risk of MACE, 
for the whole sample. Solid line presents no anti-depressant use; dashed line indicates 
anti-depressant use
Figure 2. Kaplan Meier survival curve for the use of anti-depressants on risk of MACE, 
for patients without CAD history (top) and CAD history (bottom). Solid line presents no 
anti-depressant use; dashed line indicates anti-depressant use
